Melanomas commonly undergo a phenotype switch, from a proliferative to an invasive state. Such tumor cell plasticity contributes to immunotherapy resistance; however, the mechanisms are not completely understood and thus are therapeutically unexploited. Using melanoma mouse models, we demonstrated that blocking the MNK1/2-eIF4E axis inhibited melanoma phenotype switching and sensitized melanoma to anti–PD-1 immunotherapy. We showed that phospho-eIF4E–deficient murine melanomas expressed high levels of melanocytic antigens, with similar results verified in patient melanomas. Mechanistically, we identified phospho-eIF4E–mediated translational control of NGFR, a critical effector of phenotype switching. Genetic ablation of phospho-eIF4E reprogrammed the immunosuppressive microenvironment, exemplified by lowered production of inflammatory factors, decreased PD-L1 expression on dendritic cells and myeloid-derived suppressor cells, and increased CD8+ T cell infiltrates. Finally, dual blockade of the MNK1/2-eIF4E axis and the PD-1/PD-L1 immune checkpoint demonstrated efficacy in multiple melanoma models regardless of their genomic classification. An increase in the presence of intratumoral stem-like TCF1+PD-1+CD8+ T cells, a characteristic essential for durable antitumor immunity, was detected in mice given a MNK1/2 inhibitor and anti–PD-1 therapy. Using MNK1/2 inhibitors to repress phospho-eIF4E thus offers a strategy to inhibit melanoma plasticity and improve response to anti–PD-1 immunotherapy.
Fan Huang, Christophe Gonçalves, Margarita Bartish, Joelle Rémy-Sarrazin, Mark E. Issa, Brendan Cordeiro, Qianyu Guo, Audrey Emond, Mikhael Attias, William Yang, Dany Plourde, Jie Su, Marina Godoy Gimeno, Yao Zhan, Alba Galán, Tomasz Rzymski, Milena Mazan, Magdalena Masiejczyk, Jacek Faber, Elie Khoury, Alexandre Benoit, Natascha Gagnon, David Dankort, Fabrice Journe, Ghanem E. Ghanem, Connie M. Krawczyk, H. Uri Saragovi, Ciriaco A. Piccirillo, Nahum Sonenberg, Ivan Topisirovic, Christopher E. Rudd, Wilson H. Miller Jr., Sonia V. del Rincón
Title and authors | Publication | Year |
---|---|---|
Anti-PD-1 promotes a Th1-like functional adaptation of melanoma-infiltrating regulatory T cells to alleviate immunosuppression locally.
Mikhaël Attias, Fernando Alvarez, Tho-Alfakar Al-Aubodah, Roman Istomine, Paige McCallum, Fan Huang, Abrahim Sleiman, Tamiko Nishimura, Constantin Polychronakos, Sonia Rincon, Yasser Riazalhosseini, Ciriaco Piccirillo |
Journal for immunotherapy of cancer | 2025 |
eIF4F-mediated dysregulation of mRNA translation in cancer
Amiri M, Mahmood N, Tahmasebi S, Sonenberg N |
RNA | 2025 |
SENP3 inhibition suppresses hepatocellular carcinoma progression and improves the efficacy of anti-PD-1 immunotherapy.
Wang P, Qiu J, Fang Y, Li S, Liu K, Cao Y, Zhang G, Wang Z, Gu X, Wu J, Jiang C |
Cell death and differentiation | 2025 |
Guidelines for minimal reporting requirements, design and interpretation of experiments involving the use of eukaryotic dual gene expression reporters (MINDR).
Loughran G, Andreev DE, Terenin IM, Namy O, Mikl M, Yordanova MM, McManus CJ, Firth AE, Atkins JF, Fraser CS, Ignatova Z, Iwasaki S, Kufel J, Larsson O, Leidel SA, Mankin AS, Mariotti M, Tanenbaum ME, Topisirovic I, Vázquez-Laslop N, Viero G, Caliskan N, Chen Y, Clark PL, Dinman JD, Farabaugh PJ, Gilbert WV, Ivanov P, Kieft JS, Mühlemann O, Sachs MS, Shatsky IN, Sonenberg N, Steckelberg AL, Willis AE, Woodside MT, Valasek LS, Dmitriev SE, Baranov PV |
Nature structural & molecular biology | 2025 |
MNK-driven eIF4E phosphorylation as a key regulator of the fibrogenic transformation of mesenchymal cells and chronic lung allograft dysfunction
Natalie Walker, Yuta Ibuki, Aidan P. McLinden, Keizo Misumi, Dylan C. Mitchell, Gabriel Kleer, Alison M. Lock, Ragini Vittal, Nahum Sonenberg, Amanda L. Garner, Vibha N. Lama |
Journal of Clinical Investigation | 2024 |
Tunable PhenoCycler imaging of the murine pre-clinical tumour microenvironments
Abraham MJ, Goncalves C, McCallum P, Gupta V, Preston SE, Huang F, Chou H, Gagnon N, Johnson NA, Miller WH, Mann KK, del Rincon SV |
Cell & Bioscience | 2024 |
Immune‐related adverse events in non‐small cell lung cancer: Occurrence, mechanisms and therapeutic strategies
Lin X, Xie M, Yao J, Ma X, Qin L, Zhang X, Song J, Bao X, Zhang X, Zhang Y, Liu Y, Han W, Liang Y, Jing Y, Xue X |
Clinical and Translational Medicine | 2024 |
M6A-related bioinformatics analysis indicates that LRPPRC is an immune marker for ischemic stroke.
Shen L, Yue S |
Scientific Reports | 2024 |
PPM1G dephosphorylates eIF4E in control of mRNA translation and cell proliferation.
Wang P, Li Z, Kim SH, Xu H, Huang H, Yang C, Snape A, Choi JH, Bermudez S, Boivin MN, Ferry N, Karamchandani J, Nagar B, Sonenberg N |
Life science alliance | 2024 |
Unveiling the Dynamic Interplay between Cancer Stem Cells and the Tumor Microenvironment in Melanoma: Implications for Novel Therapeutic Strategies
Limonta P, Chiaramonte R, Casati L |
Cancers | 2024 |
Blocking tumor-intrinsic MNK1 kinase restricts metabolic adaptation and diminishes liver metastasis
Preston SE, Dahabieh MS, Flores González RE, Gonçalves C, Richard VR, Leibovitch M, Dakin E, Papadopoulos T, Lopez Naranjo C, McCallum PA, Huang F, Gagnon N, Perrino S, Zahedi RP, Borchers CH, Jones RG, Brodt P, Miller WH Jr, del Rincón SV |
Science Advances | 2024 |
Second-Generation Cap Analogue Prodrugs for Targeting Aberrant Eukaryotic Translation Initiation Factor 4E (eIF4E) Activity in Drug-Resistant Melanoma
Cárdenas EL, O\u2019Rourke RL, Menon A, Vega-Hernández G, Meagher J, Stuckey J, Garner AL |
bioRxiv | 2024 |
Disrupting peroxisomes alters lipid metabolism in melanoma and uncovers a novel therapeutic vulnerability in combination with MAPK-targeted therapies
Fan Huang, Feiyang Cai, Michael S Dahabieh, Kshemaka Gunawardena, Ali Talebi, Jonas Dehairs, Farah El-Turk, Jae Yeon Park, Christophe Goncalves, Natascha Gagnon, Jie Su, Perrine Gaub, Jean-Sébastien Joyal, John J Mitchell, Johannes Swinnen, Wilson Jr., Sonia del Rincón |
Journal of Clinical Investigation | 2023 |
Escape from NK cell tumor surveillance by NGFR-induced lipid remodeling in melanoma
Lehmann J, Caduff N, Krzywińska E, Stierli S, Salas-Bastos A, Loos B, Levesque MP, Dummer R, Stockmann C, Münz C, Diener J, Sommer L |
Science Advances | 2023 |
S-adenosylmethionine blocks tumorigenesis and with immune checkpoint inhibitor enhances anti-cancer efficacy against BRAF mutant and wildtype melanomas
Mehdi A, Attias M, Arakelian A, Szyf M, Piccirillo CA, Rabbani SA |
Neoplasia (New York, N.Y.) | 2023 |
Current challenges and future directions for engineering extracellular vesicles for heart, lung, blood and sleep diseases
Li G, Chen T, Dahlman J, Eniola\u2010Adefeso L, Ghiran IC, Kurre P, Lam WA, Lang JK, Marbán E, Martín P, Momma S, Moos M, Nelson DJ, Raffai RL, Ren X, Sluijter JP, Stott SL, Vunjak\u2010Novakovic G, Walker ND, Wang Z, Witwer KW, Yang PC, Lundberg MS, Ochocinska MJ, Wong R, Zhou G, Chan SY, Das S, Sundd P |
Journal of Extracellular Vesicles | 2023 |
Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies.
Shi ZD, Pang K, Wu ZX, Dong Y, Hao L, Qin JX, Wang W, Chen ZS, Han CH |
Signal Transduction and Targeted Therapy | 2023 |
The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells.
Brina D, Ponzoni A, Troiani M, Calì B, Pasquini E, Attanasio G, Mosole S, Mirenda M, D'Ambrosio M, Colucci M, Guccini I, Revandkar A, Alajati A, Tebaldi T, Donzel D, Lauria F, Parhizgari N, Valdata A, Maddalena M, Calcinotto A, Bolis M, Rinaldi A, Barry S, Rüschoff JH, Sabbadin M, Sumanasuriya S, Crespo M, Sharp A, Yuan W, Grinu M, Boyle A, Miller C, Trotman L, Delaleu N, Fassan M, Moch H, Viero G, de Bono J, Alimonti A |
Nature cancer | 2023 |
Antigen-loaded monocyte administration and Flt3 ligand augment the antitumor efficacy of immune checkpoint blockade in a murine melanoma model
D\u2019Anniballe VM, Huang MN, Lueck BD, Nicholson LT, McFatridge I, Gunn MD |
Journal of immunotherapy (Hagerstown, Md. : 1997) | 2023 |
Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy
Cao J, Zhang Z, Zhou L, Luo M, Li L, Li B, Nice EC, He W, Zheng S, Huang C |
2023 | |
A tRF-5a fragment that regulates radiation resistance of colorectal cancer cells by targeting MKNK1.
Huang T, Chen C, Du J, Zheng Z, Ye S, Fang S, Liu K |
Journal of Cellular and Molecular Medicine | 2023 |
The expression mechanism of programmed cell death 1 ligand 1 and its role in immunomodulatory ability of mesenchymal stem cells
Chen Z, Yao MW, Ao X, Gong QJ, Yang Y, Liu JX, Lian QZ, Xu X, Zuo LJ |
Chinese Journal of Traumatology | 2023 |
Inhibiting MNK kinases promotes macrophage immunosuppressive phenotype to limit CD8+ T cell anti-tumor immunity
Thao N.D. Pham, Christina Spaulding, Mario Shields, Anastasia E Metropulos, Dhavan N. Shah, Mahmoud Khalafalla, Daniel R Principe, David Bentrem, Hidayatullah G. Munshi |
JCI Insight | 2022 |
Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition
M Berg, S del Rincón, W Miller |
Journal for ImmunoTherapy of Cancer | 2022 |
Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma
V Benboubker, F Boivin, S Dalle, J Caramel |
Frontiers in immunology | 2022 |
Overcoming Paradoxical Kinase Priming by a Novel MNK1 Inhibitor
E Bou-Petit, S Hümmer, H Alarcon, K Slobodnyuk, M Cano-Galietero, P Fuentes, P Guijarro, M Muñoz, L Suarez-Cabrera, A Santamaria, R Estrada-Tejedor, J Borrell, S y Cajal |
Journal of Medicinal Chemistry | 2022 |
Loss of YY1, a Regulator of Metabolism in Melanoma, Drives Melanoma Cell Invasiveness and Metastasis Formation
Guendisch U, Loos B, Cheng PF, Dummer R, Levesque MP, Varum S, Sommer L |
Frontiers in Cell and Developmental Biology | 2022 |
Therapeutic overexpression of miR-92a-2-5p ameliorated cardiomyocyte oxidative stress injury in the development of diabetic cardiomyopathy
Yu M, Sun Y, Shan X, Yang F, Chu G, Chen Q, Han L, Guo Z, Wang G |
Cellular & Molecular Biology Letters | 2022 |
Melanoma Plasticity: Promoter of Metastasis and Resistance to Therapy
F Huang, F Santinon, RE González, SV del Rincón |
Frontiers in Oncology | 2021 |
Optimized protocol for immunophenotyping of melanoma and tumor-bearing skin from mouse
SS Krisna, C Goncalves, N Gagnon, F Huang, D Plourde, WH Miller, JH Fritz, SV del Rincon |
2021 |